myasthenia gravis ppt

Upload: christine-almocera

Post on 04-Jun-2018

265 views

Category:

Documents


4 download

TRANSCRIPT

  • 8/13/2019 Myasthenia Gravis ppt

    1/23

    PATHOPHYSIOLOGY

  • 8/13/2019 Myasthenia Gravis ppt

    2/23

    Age

    Predisposing Factor

    Incidence of Myasthenia Gravisoccurs between ages 15-35 for

    women. (Porth p.1131)

    Our patient is 29 years old.

    Gender

    HereditaryA person born into family withhistory of certain autoimmune

    disease is at risk of developing

    such autoimmune disease.(www.emedicine.com)

    Myasthenia Gravis is three times

    more common in women than men.(Porth, p1131)

  • 8/13/2019 Myasthenia Gravis ppt

    3/23

    Precipitating Factor

    Poor environmentPoor house/ office

    Ventilationcrowded environment

    Location

    StressOccupation

    Constant exposure to dustor chemical substances can

    weaken the immune systemof every individual that

    lead to infection.(www.emedicine.com)

    Stress can weaken the immune system.According to psychoneuroimmunology, they

    found consistent stress-related increases innumbers of total white blood cell, as well asdecreases in the numbers of helper T cells,suppressor T cells, and cytotoxic T cells, Bcell, and natural killer T cells.

    (www.emedicine.com)

  • 8/13/2019 Myasthenia Gravis ppt

    4/23

    Predisposing FactorPrecipitating Factor

    Abnormal DNA mutation

    Production of abnormalT-Cells

    Difference in the variableRegion of antibodies

    Decrease # of T-cell

    Alteration of the T-cells function

  • 8/13/2019 Myasthenia Gravis ppt

    5/23

    Abnormal Antibodies

    Unable to recognize Self-antigen

    Attacking the AcetylcholineReceptor Sites

    Inhibit musclespecific Protein

    MuSK

    Malformations ofNeuromuscular

    Junction

    Destruction of AcetylcholineReceptor Sites

    Decreased PatencyOf NeuromuscularJunction

    Decrease # of functioningAcetylcholine Receptors site

  • 8/13/2019 Myasthenia Gravis ppt

    6/23

  • 8/13/2019 Myasthenia Gravis ppt

    7/23

    Myasthenia Gravis

    S/sxExpressionless faceNasal timbrePtosis

    DiplopiaDysphagiaDysarthriaDysphoniaWeakness of all Extremities

  • 8/13/2019 Myasthenia Gravis ppt

    8/23

  • 8/13/2019 Myasthenia Gravis ppt

    9/23

    A blood test for the remaining 15% of seronegative (SN) MG patients, thosewho have tested negative for the acetylcholine antibody, 40-70% testpositive for the anti-MuSK antibody. The remaining patients have anunidentified antibody causing their MG.

    Anti-MuSK Antibody testing

    Nursing DiagnosisFatigue r/t generalized muscle weakness 2 MG.

    Independent Action:

    Schedule/ organize activitiesAssist pt. with ADLs These can minimize energy expenditure and prevent injury with activities

  • 8/13/2019 Myasthenia Gravis ppt

    10/23

    Collaborative:

    Pyridostismine bromide 65mg/ tab, 1 tab t.i.d. Pyridostigmine is used to improve muscle strength in patients

    with a certain muscle disease (myasthenia gravis). It works by

    preventing the breakdown of a certain natural substance

    (acetylcholine) in your body. Acetylcholine is needed for normal

    muscle function.

    Azathioprine 50mg tab O.D.

    An immunosuppressive medication that decreases the actions of

    the bodysimmune system. Drugs that suppress the immune system

    are used in patients with myasthenia gravis because MG is an

    autoimmune disorder that results from the production of abnormal

    antibodies.

  • 8/13/2019 Myasthenia Gravis ppt

    11/23

    Prednisone 20mg, 1 tab q 12

    Prednisone is a corticosteroid hormone (glucocorticoid). It decreases your

    immune system's response to various diseases to reduce symptoms such asswelling and allergic-type reactions. It is used to treat conditions such as

    arthritis, blood disorders, breathing problems, certain cancers, eye problems,

    immune system diseases, and skin diseases.

    S/sx

    Inability to expectoraterespiratory muscle weakness

    Disruption of mechanical

    defense

    Invasion of microorganism innasal

  • 8/13/2019 Myasthenia Gravis ppt

    12/23

  • 8/13/2019 Myasthenia Gravis ppt

    13/23

    S/Sx:CoughCrackles

    Diagnostic Test

    Jan. 5 - Increased WBC-Neutrophils- 90 x10g/lLymphocytes- 4x10g/l

    Jan. 9- ETA/ GSCS result

    14-16x10g/l

    The culture result reveals that the specific type

    of bacteria called Acinetobacter baumaanii issusceptible to certain types of antibiotics such as:

    Amikacin, Ampi/Sulbactam, Ceftaxidine,

    Ciprofloxacin, Gentamicin, Ticarcillin and Tobramycin;

    hence, effective in killing these types of microorganisms.

  • 8/13/2019 Myasthenia Gravis ppt

    14/23

    Nursing Diagnosis

    Ineffective airway clearance r/t retainedtracheobronchial secretions 2 MG, CAP

    Independent Action:

    Suction secretion ,prn It mechanically clears airway in pt. who is unable

    to do so because of ineffective cough.Assist pt. in performing Deep breathing exercises Deep breathing facilitates maximum expansionof the lung areas.

    Collaborative

    Sultamicilline 150mg, 1 tab. B.i.d.Acinetobacter baumaanii is susceptible toSultamicilline

  • 8/13/2019 Myasthenia Gravis ppt

    15/23

    From MG

    If treated:MedicationsLaboratoriesSurgeriesHealth Teachings

    If treated

    Activation of immune system

    Release of Endotoxin andexotoxins

    If complaint If not compliant Inflammation of the Lungsparenchyma

    PNEUMONIAFurther distraction of

    Acetylcholine Receptorsites

    Lessen the S/sx

    Colonization of microorganism

    Invasion of microorganism in

    the lungs

  • 8/13/2019 Myasthenia Gravis ppt

    16/23

  • 8/13/2019 Myasthenia Gravis ppt

    17/23

    Nursing Diagnosis

    Risk for Aspiration r/t muscle weakness 2 MG

    Independent Action:

    Assess Gag reflex Pt. with weak gag reflex is at risk for aspiration

    Keep pt. upright for 30-60 min. after meals

    The upright position facilitates the gravitational flow offood or fluid through the alimentary tract and reduces therisk of aspiration.

    Keep suction equipment at bedside and suction necessary.

    This is necessary to maintain patent airway.

    Collaborative:Monitor ABG and pulse oximeter pulling of secretions leads to pneumonia which will lead tomore aggressive interventions.

  • 8/13/2019 Myasthenia Gravis ppt

    18/23

  • 8/13/2019 Myasthenia Gravis ppt

    19/23

    From MG

    If treated:MedicationsLaboratoriesSurgeriesHealth Teachings

    If treated

    Activation of immune system

    Release of Endotoxin andexotoxins

    If complaint If not compliant Inflammation of the Lungsparenchyma

    PNEUMONIAFurther distraction of

    Acetylcholine Receptorsites

    Lessen the S/sx

    Colonization of microorganism

    Invasion of microorganism in

    the lungs

  • 8/13/2019 Myasthenia Gravis ppt

    20/23

  • 8/13/2019 Myasthenia Gravis ppt

    21/23

    Criteria Poor(1)

    Fair

    (2)

    Good

    (3)

    Justification

    a. Duration of illness Our patient has been diagnosed withMyasthenia Gravis for more than a yearnow. She has been admitted for a few

    times due to the complications led by her

    illness.

    b. Onset of Illness During the first few weeks upon the onsetof symptoms, the patient continuedworking as a clerk. She only sought for

    medical intervention when she can no

    longer bear the symptoms she felt.

    c. Precipitating

    Factors With the precipitating factors, our patient

    has poor prognosis since her age bracket

    falls in middle adulthood (29 years old).

    Considering also that she is a female and

    such disease is common in their gender.

  • 8/13/2019 Myasthenia Gravis ppt

    22/23

    d. Willingness to takeMedications

    Our patient was able to comply with hermedications as evidenced by taking in her

    medicine on time and having sufficient

    financial resources to sustain her

    medications.

    e. Age Myasthenia Gravis commonly affects youngadult women, usually those under the age of

    40. Since our patient is 29 years old, she has

    a poor prognosis when age is considered.

    f. Environment Our patient lives in a stressful environment.Stress can trigger the remission of

    symptoms

    g. Family Support The patientsfamily is supportive. They arealways there when she needs them.

    Score: 2+2+1+3+1+1+3= 13/7=1.85 (poor - fair)

  • 8/13/2019 Myasthenia Gravis ppt

    23/23

    Based on the data, our patient got an average score of

    1.85 in 7 criteria which means poor to fair prognosis.

    In addition, both fair and good prognosis got 2 criteria

    while the precipitating factors, age, and environment got a score

    of 1 or poor prognosis. With this data, our patient is more

    susceptible for the recurrence of the disease. If this will not becorrected, this will lead to poor prognosis.

    If the patient is compliant with the treatment, she will

    have a significant improvement in her muscle weakness and

    can expect to live a normal life. If some factors such as stress

    Will be encountered then there is possible recurrence.